Results 71 to 80 of about 23,348 (143)

Pioglitazone and cause-specific risk of mortality in patients with type 2 diabetes: extended analysis from a European multidatabase cohort study. [PDF]

, 2018
OBJECTIVES: Describe and compare the risk of cardiovascular and non-cardiovascular mortality in patients whose antidiabetic therapy is modified to include pioglitazone compared with an alternative antidiabetic medication at the same stage of disease ...
Bahmanyar, Shahram, Bennett, Dimitri, Christopher, Solomon, Heintjes, Edith M, Hoti, Fabian, Korhonen, Pasi, Linder, Marie, Majak, Maila, Strongman, Helen, Williams, Rachael   +9 more
core   +1 more source

Sexual Safety Signals of Common Antidiabetic Drugs: Insights From FAERS Disproportionality Analysis

Andrology, EarlyView.
ABSTRACT Background Erectile dysfunction is a prevalent and distressing complication of diabetes mellitus that markedly affects quality of life in male patients. Although the role of diabetes in erectile dysfunction is well‐established, potential drug‐induced sexual dysfunction associated with commonly prescribed antidiabetic medications remains ...
Shan Lin, Xuefeng Ding, Xin Dang, Qingyuan Zhan   +3 more
wiley   +1 more source

Pioglitazone‐induced alterations of purine metabolism in healthy male subjects

Clinical and Translational Science
Pioglitazone is class of thiazolidinediones that activates peroxisome proliferator‐activated receptors (PPARs) in adipocytes to improve glucose metabolism and insulin sensitivity and has been used as a treatment for type 2 diabetes.
Jihyun Kang, Yufei Li, SeungHwan Lee, Kyung‐Sang Yu, Joo‐Youn Cho   +4 more
doaj   +1 more source

Glucagon-like peptide analogues for type 2 diabetes mellitus : systematic review and meta-analysis [PDF]

, 2010
Background Glucagon-like peptide (GLP-1) analogues are a new class of drugs used in the treatment of type 2 diabetes. They are given by injection, and regulate glucose levels by stimulating glucose-dependent insulin secretion and biosynthesis ...
Shyangdan, D. (Deepson), Royle, Pamela, Clar, C., Sharma, Pawana, Waugh, Norman   +4 more
core   +4 more sources

Review Article: Targeting Peroxisome Proliferator‐Activated Receptors in Primary Biliary Cholangitis

Alimentary Pharmacology &Therapeutics, EarlyView.
Peroxisome proliferator‐activated receptor (PPAR) agonists have emerged as important second‐line treatments in primary biliary cholangitis, with profiles influenced by different selectivity for α‐, δ‐ and γ‐isoforms. PPAR‐α and PPAR‐δ agonism improve cholestasis, with inflammation reduced via all isoforms. PPAR‐δ agonism also reduces pruritus.
Jörn M. Schattenberg, Jesus M. Banales, Gideon Hirschfield, Palak Trivedi, Edward E. Cable, Charles A. McWherter, Andrew N. Billin, Daria B. Crittenden, Grant Budas   +8 more
wiley   +1 more source

Effects and Potential Mechanisms of Pioglitazone on Lipid Metabolism in Obese Diabetic KKAy Mice

PPAR Research, 2014
This study aimed to analyze the effects and potential mechanisms of pioglitazone on triglyceride and cholesterol metabolism in obese diabetic KKAy mice. Pioglitazone was orally administered to KKAy mice over 30 days.
Jun Peng, Yi Huan, Qian Jiang, Su-juan Sun, Chun-ming Jia, Zhu-fang Shen   +5 more
doaj   +1 more source

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis [PDF]

, 2010
Background Nonalcoholic steatohepatitis is a common liver disease that can progress to cirrhosis. Currently, there is no established treatment for this disease.
Bass, Nathan M., Brunt, Elizabeth M., Chalasani, Naga, Clark, Jeanne, Diehl, Anna Mae, Hoofnagle, Jay H., Kleiner, David E., Kowdley, Kris V., Lavine, Joel E., McCollough, Arthur, Neuschwander-Tetri, Brent A., Robuck, Patricia R., Sanyal, Arun J., Tonascia, James, Unalp, Aynur, Van Natta, Mark   +15 more
core   +2 more sources

Diabetes management in people undergoing metabolic‐bariatric surgery: A guideline from the Joint British Diabetes Societies for Inpatient Care (JBDS‐IP) Group

Diabetic Medicine, EarlyView.
Abstract The global prevalence of obesity and diabetes continues to rise, with metabolic‐bariatric surgery recognised as an effective intervention for obesity and type 2 diabetes, offering potential for type 2 diabetes remission and improved glycaemic control. This guideline, developed by the Joint British Diabetes Societies for Inpatient Care (JBDS‐IP)
Jeffrey W. Stephens, Ketan Dhatariya, Andrew J. Beamish, Dimitri J. Pournaras, Alexander D. Miras, Nader Raafat, Georgia Noble‐Bell, Rachel Cadwallader Buckland, Omar G. Mustafa   +8 more
wiley   +1 more source

Oral diabetes medication monotherapy and short-term mortality in individuals with type 2 diabetes and coronary artery disease [PDF]

, 2018
Objective To determine whether sulfonylurea use, compared with non-sulfonylurea oral diabetes medication use, was associated with 2-year mortality in individuals with well-controlled diabetes and coronary artery disease (CAD). Research design and methods
Berkowitz, Seth A, Caplan, Liron, Grunwald, Gary K, Liu, Wenhui G, Maddox, Thomas M, Raghavan, Sridharan, Reusch, Jane E.B, Saxon, David R   +7 more
core   +3 more sources

Providing holistic care for patients with metabolic dysfunction‐associated steatotic liver disease/metabolic dysfunction‐associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and interventions

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Metabolic dysfunction‐associated steatotic liver disease (MASLD), characterised by hepatic steatosis and metabolic dysfunction (i.e., obesity, type 2 diabetes, dyslipidaemia, and hypertension), is affecting over 30% of the adult population worldwide.
Lanlan Chen, Paul Horn, Frank Tacke
wiley   +1 more source